2025
Shaw J, Hsu H, Tu H, Chia V, Aggarwal S, Carrigan G, Kelsh MA . Immortal time bias impacts time-to-time event outcomes in cohort with genomic testing. Abstract 6F-03, International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting, Washington, DC, August 2025.
View Abstract
Publication: Abstracts and Presentations
Proctor D, Jiang X, Reichert H , Thompson C. 2025. Why rat oral cavity tumors should not be the basis of quantitative cancer risk assessment for oral exposure to hexavalent chromium. Toxicol Sci kfaf112; doi: 10.1093/toxsci/kfaf112 . Online ahead of print August 8, 2025. PMID: 40795394.
View Abstract
Publication: Manuscripts
Clouser MC, Suh M , Movva N , Hildebrand JS, Pastula ST, Schoehl M, Hindoyan A, Balasubramanian A, et al. 2025. A systematic literature review of MTAP deletions in solid and hematologic cancers. Cancer Treat Res Comm 44:100966; doi: 10.1016/j.ctarc.2025.100966 .
View Abstract
Publication: Manuscripts
Allen BC, Vincent MJ, Lipworth L, Panko JM, Suh M, Jiang X , Mumma MT, Proctor DM. 2025. Lung cancer risk assessment associated with exposure to hexavalent chromium: Results of pooled analysis of three cohorts. J Occup Environ Hyg; doi: 10.1080/15459624.2025.2502491 . Online ahead of print May 28, 2025. PMID: 40435461.
View Abstract
Publication: Manuscripts
Price M, Suh M , Pastula S , Kruchko C, Ostrom Q. Pediatric low-grade glioma (pLGG) incidence in the United States from 2015 through 2019. Abstract LGG-04, Society for NeuroOncology (SNO) Pediatric Neuro-Oncology Conference, San Diego, CA, May 2025.
View Abstract
Publication: Abstracts and Presentations
Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X , Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M , Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227 ; doi: 10.1080/15459624.2024.2439817 . PMID: 39773194.
View Abstract
Publication: Manuscripts
2024
Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H , Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1 . PMID: 39695574.
View Abstract
Publication: Manuscripts
DiBiase JF, Scharnetzki E, Edelman E, Reed EK, Helbig P, Rueter J, Miesfeldt S, Frankenfeld CL , et al. 2024. Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing. JNCI Cancer Spectr 8(5):pkae090; doi: 10.1093/jncics/pkae090 . PMID: 39312685.
View Abstract
Publication: Manuscripts
Hernandez L, Davies S, Li C, Reddick E, Jensen I . A cost-consequence analysis of ponatinib versus imatinib in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia in the United States. Abstract EE165 , ISPOR 2024 (Top 5% Finalist) .
View Abstract
Publication: Abstracts and Presentations
Vincent MJ, Fitch S, Bylsma L , Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. Toxicol Sci 199(2):172–193; doi: 10.1093/toxsci/kfae039 . PMID: 38547404.
View Abstract
A Division of